Sildenafil and celecoxib interact to kill breast cancer cells
Breast cancer is the second most commonly diagnosed cancer among American women and is responsible for the second highest number of cancer-related deaths. Targeted therapeutic agents sildenafil, a phosphodiesterase type 5 inhibitor, and celecoxib, a cyclooxygenase-2 inhibitor, have been used individ...
Main Author: | Binion, Brittany |
---|---|
Format: | Others |
Published: |
VCU Scholars Compass
2014
|
Subjects: | |
Online Access: | http://scholarscompass.vcu.edu/etd/3580 http://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=4586&context=etd |
Similar Items
-
Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer
by: Meghan J. Bloom, et al.
Published: (2020-04-01) -
Lead Optimization of 2-Cyclohexyl-N-[(Z)-(3-methoxyphenyl/3-hydroxyphenyl) methylidene]hydrazinecarbothioamides for Targeting the HER-2 Overexpressed Breast Cancer Cell Line SKBr-3
by: Mashooq A. Bhat, et al.
Published: (2015-10-01) -
The Effect of Mini-PEG-Based Spacer Length on Binding and Pharmacokinetic Properties of a 68Ga-Labeled NOTA-Conjugated Antagonistic Analog of Bombesin
by: Zohreh Varasteh, et al.
Published: (2014-07-01) -
A basal level of γ-linolenic acid depletes Ca2+ stores and induces endoplasmic reticulum and oxidative stresses to cause death of breast cancer BT-474 cells
by: Cing-Yu Chen, et al.
Published: (2021-01-01) -
External beam boost versus interstitial high-dose-rate brachytherapy boost in the adjuvant radiotherapy following breast-conserving therapy in early-stage breast cancer: a dosimetric comparison
by: Martje Marie Terheyden, et al.
Published: (2016-08-01)